Clinical Trial Update: PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating AZD5718 for passivation of vulnerable plaque in acute coronary syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• AZD5718 (AZD5718)

Snippet

Sponsor: National University Heart Centre, Singapore | Conditions: Acute Coronary Syndrome | Phase 2 | Status: TERMINATED